20.10.2005 MOTION FOR A RESOLUTION to wind up the debate on the statement by the Commission pursuant to Rule 103(2) of the Rules of Procedure by Brian Crowley, Rolandas Pavilionis and Marcin Libicki on behalf of the UEN Group on patents for biotechnological inventions European Parliament resolution on patents for biotechnological inventions The European Parliament , - having regard to the 1973 European Patent Convention, in particular Article 53, point (a) thereof which precludes patenting of inventions contrary to 'ordre public' or morality, - having regard to Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions, - having regard to its resolution of 30 March 2000 on the decision by the European Patent Office with regard to patent No EP 695 351 granted on 8 December 1999 (PE 289.411), - having regard to the report from the Commission to the Council and the European Parliament entitled ‘Development and implications of patent law in the field of biotechnology and genetic engineering’ ( COM(2005)0312 ), - having regard to Article 6(2) of the Treaty on European Union, which stipulates that the Union shall respect fundamental rights, as guaranteed by the European Convention for the Protection of Human Rights and Fundamental Freedoms signed in Rome on 4 November 1950, - having regard to the report of the European Commission of July 2005 ( COM(2005)312 ), - having regard to Rule 103(2) of its Rules of Procedure, A. whereas biotechnology is playing an increasingly important role in a broad range of industries and the protection of biotechnological inventions will certainly be of fundamental importance for the Community's industrial development, B. whereas patents are essential to the promotion of innovation; C. whereas in the evolving area of biotechnology, specific appropriate rules need to be established in response; D. whereas the definition of ethically motivated limits is of particular importance in biotechnology; E. whereas the European Patent Office granted a patent on 2 February 2005 (EP 1257 168) that includes a method of selection of human germ cells and the germ cells themselves, F. whereas the European Patent Office accepted opposition against the patent EP 695 351 (Edinburgh Patent) and made clear that patents on human embryonic stem cells cannot be granted, G. whereas that decision has again been opposed, so that the legal situation is still unclear, H. whereas a too-broad granting of patents on human DNA could stifle innovation, I. whereas Article 6 of Directive 98/44/EC excludes the cloning of human beings, and the Council, in its explanatory statements to Parliament, made clear that this ban on patenting not only covers reproductive cloning and that the term ‘human being’ in this regard covers the embryonic phase, J. whereas for the creation of embryonic stem cells, embryos have to be destroyed and the patenting of technologies where human embryos are destroyed or used for commercial or industrial purposes is excluded according to Article 6(2)(c) of Directive 98/44/EC, K. whereas the public must be fully informed and the Union must play a leading role in promoting